article thumbnail

Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug

pharmaphorum

So far, human trial data for gene-editing drugs have been generated for ex vivo therapies, meaning the CRISPR technology is used to modify cells outside the body, which are then reinfused into the patient. — Eric Topol (@EricTopol) June 26, 2021. . — Eric Topol (@EricTopol) June 26, 2021.

In-Vivo 105
article thumbnail

Talem and Libera Bio partner for discovery of AI-driven antibodies

Pharmaceutical Technology

The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge. The nanocapsules are designed specifically around the antibodies’ physicochemical properties, for protecting them from degradation in the bloodstream.

Antibody 262
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

China’s NMPA clears Transcenta’s IND for solid tumour treatment

Pharmaceutical Technology

The Gremlin1 protein was found to promote lineage plasticity while driving castration resistance in prostate cancer. A synergistic activity was also observed between the anti-Gremlin1 antibody and enzalutamide against castration-resistant prostate cancer models derived from patients in vitro and in vivo.

Antibody 242
article thumbnail

STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

STAT News

Preliminary results from the study — just the second to show that CRISPR-based gene editing can be delivered systemically and performed in vivo, or inside the body — found that the treatment, NTLA-2002, reduced levels of the disease-causing protein, kallikrein, by 65% and 92% in the low- and high-dose cohort, respectively.

DNA 142
article thumbnail

Oncotarget: mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

Scienmag

All these preclinical data strongly suggest that the inhibition of mTORC1 and PLK1 proteins may be a promising therapeutic approach for NSCLC patients Credit: Correspondence to – Didier Decaudin – Didier.decaudin@curie.fr

In-Vivo 96
article thumbnail

Oncotarget: A novel format for recombinant antibody-interleukin-2 fusion proteins

Scienmag

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

article thumbnail

Leading innovators in CRISPR nucleases for the pharmaceutical industry

Pharmaceutical Technology

Cas, also called CRISPR associated proteins, are a family of nucleases such as Cas9, Cas12a, Cas12b, and CasX that process these sequences. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: CRISPR nucleases.

In-Vivo 162